ENA Respiratory is a clinical-stage pharmaceutical company developing INNA-051, a first-in-class broad-spectrum antiviral innate immunomodulator for pre- and post-exposure prophylaxis of respiratory viral infections, including COVID-19, rhinovirus and influenza in populations at-risk of complications.
The company is based in Sydney and Melbourne, Australia and it has secured a Series A investment from the Brandon Capital Partners' managed funds, the Minderoo Foundation and Uniseed.
The company is based in Sydney and Melbourne, Australia and it has secured a Series A investment from the Brandon Capital Partners' managed funds, the Minderoo Foundation and Uniseed.
Location: Australia, Victoria, Melbourne
Total raised: $24M
Founded date: 2020
Investors 2
| Date | Name | Website |
| - | Brandon Ca... | brandoncap... |
| - | Stoic VC | stoicvc.co... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 22.06.2021 | - | $24M | - |
Mentions in press and media 16
| Date | Title | Description |
| 30.04.2024 | ENA Respiratory Announces FDA IND Clearance for its Prophylactic Intranasal INNA-051 – a First-in-Class Antiviral Innate Immunomodulator | Melbourne, Australia, 29 April 2024 – ENA Respiratory, a clinical-stage pharmaceutical company developing innate immune modulators for the prevention of complications associated with respiratory viral infections in at-risk populations, anno... |
| 11.09.2023 | New Data From an Influenza Challenge Study Further Support the Prophylactic Potential of INNA-051 to Accelerate Viral Clearance | Melbourne, Australia and Milan, Italy, 11 September 2023 – ENA Respiratory, a clinical-stage pharmaceutical company, announced positive data from the Phase 2a flu challenge study of INNA-051, a first-in-class, broad-spectrum, innate immunom... |
| 14.02.2023 | Nasal Spray Significantly Accelerates Respiratory Virus Clearance in Phase 2a Clinical Study | ENA Respiratory, a clinical-stage pharmaceutical company, announced that INNA-051, a first-in-class, broad-spectrum, innate immunomodulator in development for the prophylaxis of respiratory viral infections, was found to significantly impac... |
| 12.05.2022 | ENA Respiratory Selected for BLUE KNIGHT™ to Accelerate Development of Pan-Antiviral Nasal Spray | ENA Respiratory, a clinical-stage pharmaceutical company developing INNA-051, a first-in-class broad-spectrum antiviral innate immunomodulator for pan-antiviral prophylaxis in at-risk populations and pandemic preparedness, has been selected... |
| 11.05.2022 | ENA Respiratory Selected for BLUE KNIGHT™ to Accelerate Development of Pan-Antiviral Nasal Spray | SYDNEY, Australia, May 11, 2022 (GLOBE NEWSWIRE) -- ENA Respiratory, a clinical-stage pharmaceutical company developing INNA-051, a first-in-class broad-spectrum antiviral innate immunomodulator for pan-antiviral prophylaxis in at-risk popu... |
| 16.03.2022 | First Participants Dosed in Phase 2a Study of Pan-Antiviral Nasal Spray | ENA Respiratory, a clinical-stage pharmaceutical company developing INNA-051, a first-in-class broad-spectrum antiviral innate immunomodulator for pre- and post-exposure prophylaxis of respiratory viral infections in populations at risk of ... |
| 15.03.2022 | First Participants Dosed in Phase 2a Study of Pan-Antiviral Nasal Spray | ENA Respiratory begins influenza challenge study for fast-acting nasal spray INNA-051, designed to boost innate immunity in patients at high risk of severe complications from respiratory infections SYDNEY, Australia, March 15, 2022 (GLOBE N... |
| 23.02.2022 | ENA Respiratory and the COPD Foundation Partner to Develop Pan-Antiviral Nasal Spray | ENA Respiratory, a clinical-stage pharmaceutical company developing INNA-051, a first-in-class broad-spectrum antiviral innate immunomodulator for pre- and post-exposure prophylaxis of respiratory viral infections, including COVID-19 in pop... |
| 23.02.2022 | ENA Respiratory and the COPD Foundation Partner to Develop Pan-Antiviral Nasal Spray | -- INNA-051 is being developed to stimulate innate immunity and reduce the incidence and severity of respiratory viral infections, such as COVID-19, rhinovirus, or influenza in populations at-risk of complications that include individuals w... |
| 28.09.2021 | First-in-Class, Broad-Spectrum Nasal Spray to Prevent COVID-19 and Other Common Respiratory Illnesses Set to Begin Phase 2 Trials | — ENA Respiratory engages PPD, Inc. for Phase 2 COVID-19 post-exposure prophylaxis study and hVIVO for influenza challenge study to assess the efficacy of fast-acting nasal spray designed to boost innate immunity |
Show more